Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Clofoctol
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Rectal (suppository) |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 98% |
Metabolism | Hepatic glucuronidation |
Excretion | Biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.739 |
Chemical and physical data | |
Formula | C21H26Cl2O |
Molar mass | 365.34 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.
It is only functional against Gram-positive bacteria.
It penetrates into human lung tissue.
Apteeus is developing clofoctol as a potential therapy against SARS-CoV-2.
Antibacterials: others (J01X)
| |
---|---|
Other/ungrouped |